ArticleCureus2025
Assessing the Impact: The Damage Index for Antiphospholipid Syndrome in the Context of Other Autoimmune Diseases and Cardiovascular Risk Factors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Antiphospholipid syndrome (APS) is a chronic autoimmune disorder characterized by thrombotic events and organ damage, often leading to significant morbidity and mortality. The Damage Index for Antiphospholipid Syndrome (DIAPS) was developed to quantify irreversible damage in these patients, providing a tool for better disease management. Objectives This study investigates the long-term accumulation of organ damage in patients with thrombotic APS. Specifically, it examines how damage severity differs between primary APS (PAPS) and secondary APS (SAPS) and how traditional cardiovascular risk factors contribute to disease progression. Understanding these interactions may help refine patient management strategies. Methods A retrospective analysis of 141 patients diagnosed with thrombotic APS was conducted using medical records. The DIAPS score was calculated for each patient, and its association with autoimmune comorbidities and cardiovascular risk factors was analyzed through statistical modeling. Results Among the 141 APS patients (86% female, mean age 52 years), systemic lupus erythematosus was the most frequent associated autoimmune disease (92%). Arterial hypertension was present in 39% of cases, dyslipidemia in 28%, and type 2 diabetes in 10%. Patients with SAPS had significantly higher DIAPS scores than those with PAPS (p=0.044). Hypertension and diabetes were linked to increased organ damage, while dyslipidemia influenced the relationship between APS-related autoimmunity and cumulative damage. Conclusions Patients with secondary APS experience more severe long-term damage compared to those with primary APS. Additionally, cardiovascular risk factors, particularly hypertension and diabetes, worsen disease progression. These findings underscore the need for a multidisciplinary approach that integrates autoimmune disease management with cardiovascular risk control to prevent irreversible complications in APS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.